Down syndrome is an oxidative phosphorylation disorder

M. Pilar Bayona-Bafaluy, Nuria Garrido-Pérez, Patricia Meade, Eldris Iglesias, Irene Jiménez-Salvador, Julio Montoya, Carmen Martínez-Cué, Eduardo Ruiz-Pesini

https://doi.org/10.1016/j.redox.2021.101871, Volume: 41, Pages: null

Article Type: research-article Article History

Publisher: Elsevier

- Facebook
- Twitter
- Linkedin
- Whatsapp
Altmetric

Table of Contents

1 Down syndrome and neurogenesis
2 Neurogenesis and oxidative phosphorylation
3 Oxidative phosphorylation dysfunction is an early feature of down syndrome
4 Oxidative phosphorylation-targeted therapies in down syndrome
5 Conclusions
Funding sources
Declaration of competing interest

Abstract

Down syndrome is the most common genomic disorder of intellectual disability and is caused by trisomy of chromosome 21. Several genes in this chromosome repress mitochondrial biogenesis. The goal of this study was to evaluate whether early overexpression of these genes may cause a prenatal impairment of oxidative phosphorylation negatively affecting neurogenesis. Reduction in the mitochondrial energy production and a lower mitochondrial function have been reported in diverse tissues or cell types, and also at any age, including early fetuses, suggesting that a defect in oxidative phosphorylation is an early and general event in Down syndrome individuals. Moreover, many of the medical conditions associated with Down syndrome are also frequently found in patients with oxidative phosphorylation disease. Several drugs that enhance mitochondrial biogenesis are nowadays available and some of them have been already tested in mouse models of Down syndrome restoring neurogenesis and cognitive defects. Because neurogenesis relies on a correct mitochondrial function and critical periods of brain development occur mainly in the prenatal and early neonatal stages, therapeutic approaches intended to improve oxidative phosphorylation should be provided in these periods.

•

Several chromosome 21-encoded proteins repress mitochondrial biogenesis.

•

These proteins are overexpressed in fetal brains of Down syndrome (DS) individuals.

•

Oxidative phosphorylation function is essential for neurogenesis.

•

Upregulation of these proteins adversely impact on neurogenesis.

•

Prenatal therapy with drugs inhibiting these proteins would increase DS neurogenesis.

Keywords

oxidative phosphorylation, Neurogenesis, brain development, Down syndrome, Mitochondrial biogenesis

License: CC BY

Bayona-Bafaluy,Garrido-Pérez,Meade,Iglesias,Jiménez-Salvador,Montoya,Martínez-Cué,and Ruiz-Pesini: Down syndrome is an oxidative phosphorylation disorder

1 Down syndrome and neurogenesis

Down syndrome (DS) is a multigene, multisystem disorder [1]. A partial or complete third copy of chromosome 21 (Hsa21), trisomy 21 (T21), is the major cause of DS. This condition is associated with intellectual disability, but other medical conditions, such as visual problems and hearing deficits, seizures, dementia, cardiac and muscle complications and gastrointestinal anomalies are also common in DS individuals [2,3].

Abnormalities in virtually every organ system are routinely treated in DS [4]. Intellectual disability is a key aspect of DS [4]. DS individuals show smaller brain volumes and reduced cortical surface area [1]. The brain of DS individuals exhibits a decline in proliferation and neuronal differentiation capacities of neural progenitor cells (NPCs) and an increased cell death. This deficient neurogenesis can already be observed in the fetal period [[5], [6], [7]]. To improve cognitive capabilities, active care programs using enriched environments are one of the most successful therapeutic interventions. However, results are limited and temporary [8].

2 Neurogenesis and oxidative phosphorylation

The oxidative phosphorylation (OXPHOS) system is the main energy provider to power activity of mature neurons [9]. For this reason, the central nervous system is one of the most affected tissues in OXPHOS disorders [10].

The modulation of maternal oxygenation in mice affects the fetal brain oxygen levels. Compared with normoxic brains, fetal brain volume of hypoxia-treated embryos was reduced whereas hyperoxia provoked a significant increase in brain volume [11]. Oxygen is mainly consumed by the OXPHOS system [12]. These observations suggest that OXPHOS function is also fundamental for brain development and the neurogenic process during prenatal development [13,14]. This biochemical pathway is required for neuronal differentiation [15,16]. In fact, pathological mutations in mouse or human OXPHOS-related genes impaired neuronal differentiation [[17], [18], [19]]. Confirming this effect, we have recently shown that neuronal differentiation of human cells overexpressing a mitochondrial ribosomal protein S12 (MRPS12) mutant gene was significantly reduced [20]. Moreover, the ribosomal antibiotic linezolid, that inhibits mitochondrial translation and decreases OXPHOS function, and cyanide, an OXPHOS poison, decreased neuronal differentiation of human cells [20,21].

OXPHOS system consists of mitochondrial inner membrane electron transport chain (ETC) and ATP synthase (OXPHOS complex V, CV) (Fig. 1). ETC includes respiratory complexes I to IV (CI - CIV), cytochrome c and coenzyme Q (Q). Most of the mitochondrial proteins, including all the proteins required for mitochondrial DNA (mtDNA) replication, transcription and translation; assembly proteins of OXPHOS complexes; and most of the structural subunits of the OXPHOS complexes are coded in the nuclear chromosomes (nDNA). However, 13 OXPHOS subunits are mtDNA-encoded, along with the transfer and ribosomal RNAs (tRNAs and rRNAs) needed for their production. Electrons from the nutrients reduce flavin and nicotinamide coenzymes (FAD/FADH₂ and NAD⁺/NADH) and, through CI and CII, reduce Q (ubiquinone/ubiquinol). Electrons from ubiquinol go through CIII, cytochrome c and CIV to reduce oxygen to water. The electron flow through the ETC determines the oxygen consumption and the mitochondrial inner membrane potential generated by the proton pumping from the mitochondrial matrix into the intermembrane space.

Fig. 1

Oxidative phosphorylation system (OXPHOS). ADP, adenosine diphosphate; ATP, adenosine triphosphate; Cyt c, cytochrome c; CI-IV, respiratory complexes I-IV; CV, ATP synthase; ETC, electron transport chain; e⁻, electrons; FADH₂/FAD, reduced and oxidized flavin adenine dinucleotide; H₂O, water; H⁺, protons; IM, mitochondrial inner membrane; IMS, intermembrane space; M, mitochondrial matrix; NADH/NAD⁺, reduced and oxidized nicotinamide adenine dinucleotide; OM, mitochondrial outer membrane; O₂, oxygen; Pi, phosphate; Q, coenzyme Q. Brown and pink colors are used for nDNA- and mtDNA-encoded subunits, respectively. Yellow lines, electron flow. Black arrows, proton pumping. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

3 Oxidative phosphorylation dysfunction is an early feature of down syndrome

3.1 Mouse models for down syndrome

There are several mouse models of DS [[22], [23], [24]], and some of them have been used to study neurogenesis and several mitochondrial parameters under this condition. It was published that the astrocytes of Ts1Cje mice, carriers of a trisomic segment that extends from Sod1 to Znf295 genes, showed a decrease in mitochondrial inner membrane potential and lower levels of ATP. The cerebral cortex of three-month-old Ts1Cje mice also had lower levels of ATP [25]. In Ts3Yah mice, which carry a tandem duplication of the Hspa13-App interval, there was a decrease in mRNAs of genes related to the OXPHOS system, in those related to mitochondrial biogenesis and in the amount of mtDNA in skeletal muscle [26]. The oxygen consumption with CI substrates was decreased in cerebral mitochondria of Ts65Dn mice, that harbor a trisomic segment between the App and Znf295 genes [27]. The levels of the p.MT-CO2 subunit from CIV were reduced in the soleus muscle of six-month-old Ts65Dn mice [28]. The oxygen consumption, CI and CIV activities, amount of ATP and mtDNA levels were shown decreased in NPCs of Ts65Dn mice. The impairment of the OXPHOS system was accompanied by a decrease in neuronal proliferation and differentiation capacity that has been suggested to be responsible for the reduced neuronal density found in the Ts65Dn mouse [[29], [30], [31]].

3.2 Down syndrome individuals

Several studies using differentiated cells from T21 human induced pluripotent stem cells (hiPSCs) showed that these models reflect the molecular and cellular phenotypes observed in primary cells and in individuals with DS [32]. T21 hiPSCs-derived neurons showed decreased mitochondrial inner membrane potential and increased production of amyloid peptide [33]. A reduction in mitochondrial inner membrane potential was also informed in lymphocytes and lymphoblastic cell lines from DS individuals [34,35], and also in neurons, astrocytes and fibroblasts of DS fetuses from 14 to 22 weeks of gestation [[36], [37], [38], [39], [40]]. A decrease in oxygen consumption was reported in fibroblasts and lymphocytes of DS individuals and fibroblasts of DS fetuses from 14 to 22 weeks of gestation [37,39,[41], [42], [43], [44], [45]]. The activity of ETC complexes was found decreased in fibroblasts, lymphocytes and platelets of DS individuals and fibroblasts of DS fetuses from 14 to 22 weeks of gestation [37,41,[43], [44], [45], [46], [47]]. The quantity of protein subunits for OXPHOS complexes was also reduced in brain, cerebellum and fibroblasts of DS adults or DS fetuses from 14 to 19 weeks of gestation [41,[48], [49], [50], [51]]. A lower Q quantity was reported in lymphocytes, platelets and plasma of DS individuals [52,53]. mRNA levels of a number of genes coding subunits of the OXPHOS complexes were decreased in T21 hiPSCs [54]. Supporting these data, a reduction in mRNA levels of several subunits of OXPHOS complexes was reported in DS cerebellum and fibroblasts [55,56]. Very interestingly, the down-regulation of genes for all OXPHOS complexes was also found in heart, fibroblasts and amniocytes of DS fetuses from 8 to 22 weeks of gestation [43,51,57,58]. This decline in mRNA levels was accompanied by a lower transcription of mtDNA-encoded genes and by a lower amount of mtDNA in brain from individuals with DS and Alzheimer disease (DSAD) and in DS fetuses of 22 weeks of gestation [59,60]. The levels of gene transcripts encoded in mtDNA were also found reduced in differentiated neurons from NPCs of DS individuals. This fact was accompanied by a reduced proliferative rate and a deviation of neuronal differentiation towards astrocytes [61].

All these modifications give place to a reduction in the mitochondrial energy production and a lower mitochondrial function [35,38,39,41,44,45,62,63]. As it can be noted from all these publications, OXPHOS defects were reported in distinct species, diverse tissues or cell types, and also at any age, including early fetuses. Therefore, it can be deduced that this defect is not a side effect but an early and general event in DS individuals. Moreover, many of the medical conditions associated with DS are also frequently found in patients with OXPHOS disease [64]. Thus, ‘red-flag’ features, which warrant the initiation of a baseline diagnostic evaluation for mitochondrial disease [65,66], such as epilepsia, intestinal dysmotility and hypotonia are also observed in DS individuals [2,3]. A multitude of other nonspecific symptoms that frequently occur in patients with mitochondrial disease [65,66], such as short stature, hearing loss, hypothyroidism and autism spectrum disorder (ASD) are also found in DS individuals [2,3]. Interestingly, similar to DS, ASD is a neurodevelopmental condition and the affectation of neurogenesis begins in the prenatal stage [67]. Moreover, an OXPHOS dysfunction is also found in ASD [68,69]. For all the aforementioned reasons, DS can be considered as an OXPHOS disorder.

The overexpression of genes from Hsa21 is responsible for the DS pathogenesis. Some of these genes play a role in the expression of other genes and many of them are involved in the OXPHOS function. One of these genes is the amyloid precursor protein (APP) gene that is located in the chromosomal band 21q21.3 (Fig. 2A). This gene is overexpressed in different cell types from DS individuals [70,71]. While iPSCs had transcriptome profiles comparable to that of normal fetal brain development [61], T21 iPSCs had a marked upregulation of APP expression [61,72,73]. Moreover, its expression was also upregulated in NPCs, astrocytes and neurons derived from T21 hiPSCs [71,74]. Increased APP, and its carboxy-terminal fragment 99 (CTF99), levels were found in primary DS fetal brain cultures [36]. Increased APP mRNA and protein levels have been also detected in brains of fetuses with DS [[75], [76], [77], [78], [79]]. Moreover, amyloid beta (Aβ) was detected in fetuses with DS, but not in age-matched controls [80]. Increased CTF levels were also found in the brains of fetuses with DS [81]. The APP protein can associate with components of the mitochondrial protein translocation machinery and prevent the import of mitochondrial proteins, including nDNA-encoded OXPHOS subunits. Additionally, the APP-derived peptides, such as Aβ, amyloid precursor protein intracellular domain (AICD), and CTF99 can be present in mitochondria, interact with OXPHOS components and mtDNA and have detrimental consequences on bioenergetics function [82,83].

Fig. 2

Chromosome 21 genes that repress mitochondrial biogenesis. A) Chromosome 21 location of genes that affect the oxidative phosphorylation function. Some of them, indirectly, through a negative effect on mitochondrial biogenesis (red color). B) Chromosome 21-endoced proteins that block mitochondrial biogenesis. Mitochondrial biogenesis leads to an overall increase in ATP synthesis. Neurogenesis requires high amount of energy. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

The cystathionine β synthase (CBS) gene is located in the 21q22.3 chromosomal band (Fig. 2A). This enzyme is responsible for the production of the gaseous transmitter hydrogen sulfide (H₂S). An increased expression of CBS in many cells and tissues, including the brain, and H₂S overproduction are well documented in DS individuals [71,[84], [85], [86], [87], [88], [89], [90], [91], [92]]. Human fetal brains from DS individuals showed increased CBS mRNA levels [78]. It was shown that a chronic exposure of pregnant wildtype animals to inhaled H₂S produced significant neurodevelopmental alterations. This compound is an inhibitor of the respiratory CIV [92].

The liver type phosphofructokinase (PFK) gene, located in the chromosomal band 21q22.3 (Fig. 2A), is overexpressed in different cell types and the brain of DS individuals [70,74,88,91]. Its enzyme activity was shown increased in erythrocytes and fibroblasts from DS individuals [[93], [94], [95]]. PFK overexpression negatively regulated neurogenesis from NSCs and inhibited their neuronal differentiation [96]. PFK could play a key role in regulating the metabolic balance between glycolysis and OXPHOS [97].

The dual specificity tyrosine phosphorylation regulated kinase 1 A (DYRK1A) gene coded in the chromosomal band 21q22.13 (Fig. 2A) is overexpressed in different cell types [[70], [71], [72],74,79,98,99], adult brains [88,91,[100], [101], [102], [103]] and fetal brains of DS individuals [78,104,105]. An increase of DYRK1A protein and activity was found in NPCs derived of T21 hiPSCs obtained from fetal fibroblasts [6]. DYRK1A overexpression reduced the nuclear factor of activated T-cells (NFATc) activity (Fig. 2B) [43,106]. NFATc exerts a positive effect on the promoter of the peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC-1α or PPARGC1A) gene [107], which is a key modulator of mitochondrial biogenesis and OXPHOS function [108]. Therefore, high DYRK1A levels might reduce mitochondrial biogenesis.

The regulator of calcineurin 1 (RCAN1) gene, located in the chromosomal band 21q22.12 (Fig. 2A), is overexpressed in different cell types and the brain of DS individuals [70,72,88,99]. It is also overexpressed in different DS fetal cells and tissues, such as cultured amniocytes and chorionic villus cells [109,110], fibroblasts [111], liver and kidney [112], and brain [113]. Moreover, neural cells derived from T21 hiPSCs obtained from amniotic fluid stem cells overexpressed RCAN1 [114]. In Drosophila melanogaster, the overexpression of the RCAN1 homolog gene, nebula, reduced CIV activity and mitochondrial DNA content [59]. In embryonic rat striatal neurons ST14A, Rcan1 overexpression leaded to a reduction in mitochondrial mass and oxygen consumption rate [115]. The β-cells of mice overexpressing Rcan1 displayed reduced OXPHOS function [116]. In human umbilical vein endothelial cells (HUVEC) and cardiomyocytes, RCAN1 overexpression decreased mitochondrial mass [117,118]. In human neuroblastoma SH-SY5Y cells overexpressing RCAN1, oxygen consumption rate was decreased [119]. In addition, RCAN1 overexpression reduced NFATc activity (Fig. 2B and Table 1) [106].

Table 1

Effect on OXPHOS function of the over- or under-expression of particular Hsa21 genes related to mitochondrial biogenesis.

The nuclear receptor interacting protein 1 (NRIP1) gene, which is located in 21q11.2-q21.1 chromosomal band (Fig. 2A), codes for a transcriptional corepressor protein. This gene is overexpressed in different cell types from DS individuals [70,71]. NRIP1 overexpression has been documented in fetal brains and fibroblasts of DS individuals [79,120,121]. It has been shown that Nrip1 levels affect OXPHOS function and mitochondrial biogenesis in different cells and tissues of mice and rats [[122], [123], [124], [125], [126], [127], [128], [129], [130], [131], [132], [133], [134], [135], [136], [137]]. A bias towards OXPHOS in human embryonic stem cells (hESCs) is consistent with increased PPARGC1A and decreased NRIP1 expression [138]. The NRIP1 overexpression in DS fetal fibroblasts represses PPARGC1A and decreases mRNA levels of many OXPHOS-related genes (Fig. 2B and Table 1) [120].

The PBX/knotted 1 homeobox 1 (PKNOX1) gene, located in the chromosomal band 21q22.3 (Fig. 2A), is overexpressed in different cell types from DS individuals [70], and fetal brain and fibroblasts of DS individuals [139,140]. This gene codes for a homeodomain transcription factor. Its muscle-specific ablation resulted in increased expression of ETC subunits, higher enzyme activity, and elevated PPARGC1A expression (Fig. 2B and Table 1) [141].

The BTB domain and CNC homolog 1 (BACH1) gene is located in 21q21.3 chromosomal band (Fig. 2A). This gene is overexpressed in different cell types from DS individuals [70,71,79,142]. It is also overexpressed in DS adult and fetal brain [88,91,143]. BACH1, a haem-binding transcription factor, binds to promoter regions of ETC genes and negatively regulates their transcription, thus reducing mitochondrial respiration [144]. On the contrary, the loss of BACH1 promotes mitochondrial respiration [144]. BACH1 is also a repressor of nuclear-erythroid-derived 2-like 2 (NRF2 or NFE2L2)-induced genes. NFE2L2 displaces BACH1 and upregulates a battery of genes. The PPARGC1A promoter contains NFE2L2 consensus sequences [145]. Therefore, BACH1 negatively regulates mitochondrial biogenesis (Fig. 2B and Table 1).

These observations suggest that several Hsa21 genes negatively regulate the PPARGC1A expression and/or activity [146], as shown in second trimester amniocytes derived from humans with DS [79]. This PPARGC1A downregulation would reduce mitochondrial biogenesis and lead to an OXPHOS defect.

4 Oxidative phosphorylation-targeted therapies in down syndrome

Critical periods of brain development, including neurogenesis and synapse formation, occur mainly in the prenatal and early neonatal stages. As already indicated, permanent neuromorphological alterations originate during fetal life in DS. Thus, this may be the period to positively impact neurogenesis and significantly improve the postnatal cognitive outcome in DS [4,29,32,147,148].

4.1 Mitochondrial biogenesis inducers

It has been shown that the activation of PPARGC1A and mitochondrial biogenesis protects against prenatal hypoxic-ischemic brain injury [149]. Similar therapies targeting mitochondria have shown to be beneficial in the treatment of DS phenotypes [[150], [151], [152]]. In the same way, the inhibition of overexpressed proteins in DS that reduce OXPHOS function, such as CBS, or mitochondrial biogenesis, such as DYRK1A, might be tested as a potential early therapy [153,154].

It was previously mentioned that PFK knockdown enhanced neuronal differentiation of NSCs and increased neurogenesis in the dentate gyrus of the mouse hippocampus [96]. It has been recently reported that tryptolinamide, a PFK inhibitor, activated mitochondrial respiration and rescued the defect in neuronal differentiation of iPSCs carrying mutant mtDNAs [97].

The promotion of mitochondrial biogenesis is an interesting therapeutic approach. Many drugs, such as epigallocatechin-3-gallate (EGCG), metformin, resveratrol, pioglitazone, β-guanadinopropionic acid (β-GPA) and 2,4-dinitrophenol (DNP) increase the PPARGC1A levels [30,39,146,155,156]. EGCG is a DYRK1A inhibitor and induces mitochondrial biogenesis (Fig. 3) [[157], [158], [159]]. This compound stimulated OXPHOS function in fibroblasts and lymphoblasts of DS individuals [44]. EGCG reversed the mitochondrial energetic deficit and rescued the altered neurogenesis of NPCs from a mouse model of DS or from T21 hiPSCs [6,30]. EGCG improved neurogenesis after ischemic stroke in adult mice [160]. Moreover, neonatal or prenatal treatment with EGCG restored neurogenesis and cognitive defects in mouse models of DS [161,162]. A mix of EGCG and omega-3 fatty acids restored ETC activity in lymphocytes from a DS child [163].

Fig. 3

Inducers of mitochondrial biogenesis. Chromosome 21-encoded proteins that repress mitochondrial biogenesis are shown in red color. PPARGC1A, one of the main factors involved in mitochondrial biogenesis is represented in green color. Drugs enhancing mitochondrial biogenesis are indicated in blue color. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

Omega-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) increased the Ppargc1a expression and mitochondrial biogenesis in the mouse C2C12 myoblast cell line [164]. Omega-3 containing fish oil supplementation starting at conception led to a reduction in hippocampal Rcan1 mRNA and protein levels in 1.5-month-old mice [165]. The prenatal administration of the omega-3 alpha-linolenic acid, that also increase PPARGC1A expression and mitochondrial biogenesis in fat of mice [166,167] and in human SH-SY5Y cells [168], reduced neuromorphological and cognitive alterations in Ts65Dn mice [169]. Alpha-linolenic acid is required in fetal stages of brain development in mice [170].

In mouse C2C12 cells, metformin downregulated NRIP1 and augmented the Ppargc1a levels (Fig. 3) [171]. Metformin also induced mitochondrial biogenesis in human aortic endothelial cells [172], stimulated OXPHOS function in fibroblasts of DS individuals [39], and improved neurogenesis of human bone marrow-mesenchymal stem cells [173]. β-GPA feeding led to marked reductions in both the protein content and mRNA expression of Nrip1 in fast-twitch rat triceps muscles and increased mitochondrial proteins, such as COXI, COXIV, and CS (Fig. 3) [127]. β-GPA treatment increased the mtDNA copy number in the cortex and ventral midbrain of mice, as well as the expression of several key metabolic enzyme indicators of mitochondria proliferation and the activation of Nfe2l2 signaling cascade [174].

Also related to an Hsa21 gene involved in mitochondrial biogenesis, hemin, the active ingredient of the FDA-approved drug Panhematin, binds to BACH1 and favors its release from DNA for nuclear export and subsequent degradation. It has been shown that hemin increased mitochondrial gene expression and induced oxygen consumption rate in triple negative breast cancer cells (Fig. 3) [144]. Kelch-like ECH associated protein 1 (KEAP1) sequesters NFE2L2 in the cytoplasm. In the presence of dimethylfumarate (DMF), KEAP1 is modified allowing NFE2L2 translocation to the nucleus and the dissociation of BACH1. It has been shown in mouse embryonic fibroblasts that DMF induced mitochondrial biogenesis and increased the mtDNA copy number, the transcription levels of mtDNA-encoded genes and the amount of OXPHOS subunits [175]. Interestingly, several pharmacologic therapies, such as fluoxetine, curcumin and apigenin have been already prenatally tested in mouse models of DS and shown to have beneficial effects on neurogenesis and behavioral performance [[176], [177], [178]]. These three drugs have been shown to improve OXPHOS function and mitochondrial biogenesis [[179], [180], [181], [182], [183], [184], [185]]. Although none of them has been related to the chromosome 21 genes that repress mitochondrial biogenesis, all of them increase the expression of NFE2L2 [[186], [187], [188], [189], [190], [191]].

Resveratrol and pioglitazone are inducers of mitochondrial biogenesis (Fig. 3) [158,192,193]. Pioglitazone stimulated OXPHOS function in fibroblasts of DS individuals [194], and improved neurogenesis of human neuroblastoma SH-SY5Y cells [195]. Resveratrol reversed the mitochondrial energetic deficit and rescued the altered neurogenesis of NPCs from a mouse model of DS [30].

Finally, the DNP activates mitochondrial biogenesis in mice and rats [196,197], and in human rhabdomyosarcoma cells (Fig. 3) [156]. DNP is a mild OXPHOS uncoupler that increased the synthesis of pyrimidine nucleotide-derived compounds to produce phospholipids, neuritogenesis and neuronal differentiation [[198], [199], [200]]. Interestingly, it was shown that the total phospholipid content was significantly reduced in central cortex and cerebellum of DS individuals [201]. It has been also reported that cerebral cortex cells (CTb) derived from mouse fetuses with trisomy 16, an animal model of DS, overexpressed App, because this protein is coded in the mouse chromosome 16 (Mmu16). DNP decreased intracellular accumulation of App in these cells [202].

In mouse hippocampus, the ketogenic diet upregulated the Ppargc1a mRNA and protein levels and other markers of mitochondrial biogenesis [203]. In cells from other species, including human fibroblasts, β-hydroxybutyrate increased the PPARGC1A levels and oxygen consumption [203]. In pigs, maternal ketosis increased fetal brain weight [204]. The ketogenic diet during the prenatal and early postnatal periods had beneficial effects on the brain development of pyruvate dehydrogenase complex-deficient mammalian progeny [205]. The ketogenic diet has been proposed as a potential therapeutic option for DS individuals [206].

4.2 OXPHOS products

Pyrimidine nucleotides are needed for RNA synthesis and, after reduction to deoxyribonucleotides, for DNA synthesis. In addition, these nucleotides are fundamental for the activation of the sugars that will give rise to the glycoproteins and glycolipids of the plasma membrane and also for the activation of compounds that will produce phospholipids and related molecules for the production of membrane lipids [21,207]. Uridine nucleotides are also involved in the N-acetylglucosamination of many proteins. If this process in disrupted, intellectual disability may ensue [208]. Pyrimidine nucleotides are essential in proliferating cells. On the other hand, neurons are non-proliferating differentiated cells. Its differentiation process includes the formation of axons and dendrites and the maintenance of its huge surface that requires a continuous membrane synthesis, even in already differentiated neurons [209]. Dihydroorotate dehydrogenase (DHODH) links the de novo pyrimidine biosynthesis pathway and OXPHOS function. Ubiquinone is the electrons’ acceptor in the oxidation of dihydroorotate to orotate by the DHODH [21,207]. A Q deficiency, as previously reported in DS, impairs the de novo synthesis of pyrimidine nucleotides [210]. DSAD individuals show a reduction in plasma uridine concentrations [211]. Hence, a deficit of the OXPHOS system hampering Q reoxidation might cause a reduction in the de novo pyrimidine biosynthesis [212], in the proliferation of neuronal precursor cells and in their differentiation into neurons. We observed that uridine was able to prevent the negative effects of OXPHOS dysfunction on neuronal differentiation. Uridine prevented the decline of neuronal differentiation in cells overexpressing a mutant MRPS12 gene, in linezolid-treated cells, in linezolid-treated cells overexpressing a mutant MRPS12 gene, or in cyanide-treated cells [20,21].

The choline prenatal administration has shown to have beneficial effects on neurogenesis and behavioral performance when tested in a mouse model of DS [213]. Along with cytidine triphosphate (CTP), derived from uridine triphosphate (UTP), choline is required for phospholipid synthesis and brain development [21,214]. Therefore, choline or uridine administration could increase this process [215].

5 Conclusions

Although DS is a multigenic disorder and many cell pathways are affected, the early prenatal OXPHOS dysfunction is a key pathologic mechanism in the intellectual disability. Moreover, OXPHOS is a ubiquitous cell function and its deficiency might affect every organ of the body and hence, be related to many of the medical conditions associated to DS. Therefore, any strategy developed to improve OXPHOS function could become a successful therapeutic approach in DS.

The invitation to pregnant women to participate in trials for fetal DS therapy should be based on adequate preclinical evidence. There should be convincing experimental evidence based on cell and animal studies that ensures the safety and efficacy of the therapy [4]. These models, with their related problems, are considered suitable approaches for the study of human pathophysiology and response to drugs in DS [23,24,32]. To test this hypothesis, the overexpression of each one of these genes that repress mitochondrial biogenesis in cells capable of differentiate into neurons would help to study their effect on OXPHOS function and on neurogenesis. On the other hand, iPSCs from DS individuals would allow to analyze the combined effect of all these genes on OXPHOS function and neuronal differentiation. The effect of the proposed drugs on these cellular parameters would also be studied in both cell models. If promising results are obtained, mouse models with DS would allow to study the prenatal effect of the proposed drugs. In fact, some results obtained with prenatal therapy in animal models encourage to dedicate more time, effort and resources in this field [216]. Finally, some of the proposed drugs have been demonstrated to be safe, have been approved and are normally administered in pregnant women for the treatment of other pathologies.

Funding sources

This work was supported by grants from 10.13039/501100004587Instituto de Salud Carlos III [FIS-PI17/00021, FIS-PI17/00166]; Fundación Mutua Madrileña [MMA17/01]; Precipita-FECYT crowdfunding program [PR194]; Gobierno de Aragón [LMP135_18, Grupos Consolidados B33_17R] and 10.13039/501100002924FEDER 2014–2020 “Construyendo Europa desde Aragón”. CIBERER is an initiative of the ISCIII. The sponsors had no role in the study design, collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

Baburamani

A.A.

, Patkee

P.A.

, Arichi

, Rutherford

M.A.

. New approaches to studying early brain development in Down syndrome.

doi: 10.1111/dmcn.14260

Antonarakis

S.E.

, Skotko

B.G.

, Rafii

M.S.

, Strydom

, Pape

S.E.

, Bianchi

D.W.

, Sherman

S.L.

, Reeves

R.H.

. Down syndrome.

doi: 10.1038/s41572-019-0143-7

Bull

M.J.

. Down syndrome.

doi: 10.1056/NEJMra1706537

de Wert

, Dondorp

, Bianchi

D.W.

. Fetal therapy for Down syndrome: an ethical exploration.

doi: 10.1002/pd.4995

Guidi

, Bonasoni

, Ceccarelli

, Santini

, Gualtieri

, Ciani

, Bartesaghi

. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome.

doi: 10.1111/j.1750-3639.2007.00113.x

Hibaoui

, Grad

, Letourneau

, Sailani

M.R.

, Dahoun

, Santoni

F.A.

, Gimelli

, Guipponi

, Pelte

M.F.

, Béna

, Antonarakis

S.E.

, Feki

. Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21.

doi: 10.1002/emmm.201302848

Stagni

, Giacomini

, Emili

, Guidi

, Bartesaghi

. Neurogenesis impairment: an early developmental defect in Down syndrome.

doi: 10.1016/j.freeradbiomed.2017.07.026

Martínez Cué

, Dierssen

Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome

Elsevier B.V.

doi: 10.1016/bs.pbr.2019.11.001

Hall

C.N.

, Klein-Flugge

M.C.

, Howarth

, Attwell

. Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing.

doi: 10.1523/JNEUROSCI.0026-12.2012

Keshavan

, Rahman

. Natural history of mitochondrial disorders: a systematic review.

doi: 10.1042/EBC20170108

Wagenfuhr

, Meyer

A.K.

, Braunschweig

, Marrone

, Storch

. Brain oxygen tension controls the expansion of outer subventricular zone-like basal progenitors in the developing mouse brain.

doi: 10.1242/dev.121939

Keeley

T.P.

, Mann

G.E.

. Defining physiological normoxia for improved translation of cell physiology to animal models and humans.

doi: 10.1152/physrev.00041.2017

Khacho

, Clark

, Svoboda

D.S.

, MacLaurin

J.G.

, Lagace

D.C.

, Park

D.S.

, Slack

R.S.

. Mitochondrial dysfunction underlies cognitive defects as a result of neural stem cell depletion and impaired neurogenesis.

doi: 10.1093/hmg/ddx217

Khacho

, Harris

, Slack

R.S.

. Mitochondria as central regulators of neural stem cell fate and cognitive function.

doi: 10.1038/s41583-018-0091-3

O'Brien

L.C.

, Keeney

P.M.

, Bennett

J.P.

. Differentiation of human neural stem cells into motor neurons stimulates mitochondrial biogenesis and decreases glycolytic flux.

1984–1994

doi: 10.1089/scd.2015.0076

Lorenz

, Prigione

. Mitochondrial metabolism in early neural fate and its relevance for neuronal disease modeling.

doi: 10.1016/j.ceb.2017.12.004

Kirby

D.M.

, Rennie

K.J.

, Smulders-Srinivasan

T.K.

, Acin-Perez

, Whittington

, Enriquez

J.-A.

, Trevelyan

A.J.

, Turnbull

D.M.

, Lightowlers

R.N.

. Trans mitochondrial embryonic stem cells containing pathogenic mtDNA mutations are compromised in neuronal differentiation.

doi: 10.1111/j.1365-2184.2009.00612.x

Hatakeyama

, Goto

. Concise review: heteroplasmic mitochondrial DNA mutations and mitochondrial diseases: toward iPSC-based disease modeling, drug discovery, and regenerative therapeutics.

doi: 10.1002/stem.2292

Yokota

, Hatakeyama

, Ono

, Kanazawa

, Goto

. Mitochondrial respiratory dysfunction disturbs neuronal and cardiac lineage commitment of human iPSCs.

doi: 10.1038/cddis.2016.484

Iglesias

, Bayona-Bafaluy

M.P.

, Pesini

, Garrido-Pérez

, Meade

, Gaudó

, Jiménez-Salvador

, Montoya

, Ruiz-Pesini

. Uridine prevents negative effects of OXPHOS xenobiotics on dopaminergic neuronal differentiation.

doi: 10.3390/cells8111407

Pesini

, Iglesias

, Bayona-Bafaluy

M.P.

, Garrido-Pérez

, Meade

, Gaudó

, Jiménez-Salvador

, Andrés-Benito

, Montoya

, Ferrer

, Pesini

, Ruiz-Pesini

. Brain pyrimidine nucleotide synthesis and Alzheimer disease.

doi: 10.18632/aging.102328

Rueda

, Flórez

, Martínez-Cué

. Mouse models of down syndrome as a tool to unravel the causes of mental disabilities.

doi: 10.1155/2012/584071

Herault

, Delabar

J.M.

, Fisher

E.M.C.

, Tybulewicz

V.L.J.

, Yu

, Brault

. Rodent models in Down syndrome research: impact and future opportunities.

doi: 10.1242/dmm.029728

Zhao

, Bhattacharyya

. Human models are needed for studying human neurodevelopmental disorders.

doi: 10.1016/j.ajhg.2018.10.009

Shukkur

E.A.

, Shimohata

, Akagi

, Yu

, Yamaguchi

, Murayama

, Chui

, Takeuchi

, Amano

, Subramhanya

K.H.

, Hashikawa

, Sago

, Epstein

C.J.

, Takashima

, Yamakawa

. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome.

doi: 10.1093/hmg/ddl211

Brault

, Duchon

, Romestaing

, Sahun

, Pothion

, Karout

, Borel

, Dembele

, Bizot

J.-C.

, Messaddeq

, Sharp

A.J.

, Roussel

, Antonarakis

S.E.

, Dierssen

, Hérault

. Opposite phenotypes of muscle strength and locomotor function in mouse models of partial trisomy and monosomy 21 for the proximal Hspa13-App region.

e1005062

doi: 10.1371/journal.pgen.1005062

Bambrick

L.L.

, Fiskum

. Mitochondrial dysfunction in mouse trisomy 16 brain.

doi: 10.1016/j.brainres.2007.10.045

Cowley

P.M.

, Keslacy

, Middleton

F.A.

, DeRuisseau

L.R.

, Fernhall

, Kanaley

J.A.

, DeRuisseau

K.C.

. Functional and biochemical characterization of soleus muscle in Down syndrome mice: insight into the muscle dysfunction seen in the human condition.

doi: 10.1152/ajpregu.00312.2012

Bartesaghi

, Guidi

, Ciani

. Is it possible to improve neurodevelopmental abnormalities in Down syndrome?.

doi: 10.1515/RNS.2011.037

Valenti

, de Bari

, de Rasmo

, Signorile

, Henrion-Caude

, Contestabile

, Vacca

R.A.

. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.

doi: 10.1016/j.bbadis.2016.03.003

Valenti

, Rossi

, Marzulli

, Bellomo

, De Rasmo

, Signorile

, Vacca

R.A.

. Inhibition of Drp1-mediated mitochondrial fission improves mitochondrial dynamics and bioenergetics stimulating neurogenesis in hippocampal progenitor cells from a Down syndrome mouse model.

doi: 10.1016/j.bbadis.2017.09.014

Lee

S.E.

, Duran-Martinez

, Khantsis

, Bianchi

D.W.

, Guedj

. Challenges and opportunities for translation of therapies to improve cognition in down syndrome.

doi: 10.1016/j.molmed.2019.10.001

Murray

, Letourneau

, Canzonetta

, Stathaki

, Gimelli

, Sloan-Bena

, Abrehart

, Goh

, Lim

, Baldo

, Dagna-Bricarelli

, Hannan

, Mortensen

, Ballard

, Syndercombe Court

, Fusaki

, Hasegawa

, Smart

T.G.

, Bishop

, Antonarakis

S.E.

, Groet

, Nizetic

. Brief report: isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration.

2077–84

doi: 10.1002/stem.1968

Abu Faddan

, Sayed

, Ghaleb

. T lymphocytes apoptosis and mitochondrial membrane potential in Down's syndrome.

doi: 10.3109/15513815.2010.505626

Coskun

, Helguera

, Nemati

, Bohannan

R.C.

, Thomas

, Samuel

S.E.

, Argueta

, Doran

, Wallace

D.C.

, Lott

I.T.

, Busciglio

. Metabolic and growth rate alterations in lymphoblastic cell lines discriminate between down syndrome and alzheimer's disease.

doi: 10.3233/JAD-160278

Busciglio

, Pelsman

, Wong

, Pigino

, Yuan

, Mori

, Yankner

B.A.

. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome.

doi: 10.1016/s0896-6273(02)00604-9

Valenti

, Manente

G.A.

, Moro

, Marra

, Vacca

R.A.

. Deficit of complex I activity in human skin fibroblasts with chromosome 21 trisomy and overproduction of reactive oxygen species by mitochondria: involvement of the cAMP/PKA signalling pathway.

doi: 10.1042/BJ20101908

Helguera

, Seiglie

, Rodriguez

, Hanna

, Helguera

, Busciglio

. Adaptive downregulation of mitochondrial function in down syndrome.

doi: 10.1016/j.cmet.2012.12.005

Izzo

, Nitti

, Mollo

, Paladino

, Procaccini

, Faicchia

, Calì

, Genesio

, Bonfiglio

, Cicatiello

, Polishchuk

, Pinton

, Matarese

, Conti

, Nitsch

. Metformin restores the mitochondrial network and reverses mitochondrial dysfunction in Down syndrome cells.

doi: 10.1093/hmg/ddx016

Takahashi

, Moriyama

, Nakamura

, Miki

, Takahashi

, Sato

, Akaike

, Itto-Nakama

, Arimoto

. AUTACs: cargo-specific degraders using selective autophagy.

doi: 10.1016/j.molcel.2019.09.009

Valenti

, Tullo

, Caratozzolo

M.F.

, Merafina

R.S.

, Scartezzini

, Marra

, Vacca

R.A.

. Impairment of F1F0-ATPase, adenine nucleotide translocator and adenylate kinase causes mitochondrial energy deficit in human skin fibroblasts with chromosome 21 trisomy.

doi: 10.1042/BJ20100581

Aburawi

E.H.

, Souid

A.-K.

. Lymphocyte respiration in children with Trisomy 21.

doi: 10.1186/1471-2431-12-193

Piccoli

, Izzo

, Scrima

, Bonfiglio

, Manco

, Negri

, Quarato

, Cela

, Ripoli

, Prisco

, Gentile

, Calì

, Pinton

, Conti

, Nitsch

, Capitanio

. Chronic pro-oxidative state and mitochondrial dysfunctions are more pronounced in fibroblasts from Down syndrome foeti with congenital heart defects.

doi: 10.1093/hmg/dds529

Valenti

, De Rasmo

, Signorile

, Rossi

, de Bari

, Scala

, Granese

, Papa

, Vacca

R.A.

. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome.

doi: 10.1016/j.bbadis.2012.12.011

Panagaki

, Randi

E.B.

, Augsburger

, Szabo

. Overproduction of H2S, generated by CBS, inhibits mitochondrial Complex IV and suppresses oxidative phosphorylation in Down syndrome.

18769–18771

doi: 10.1073/pnas.1911895116

Solmi

, Rossetti

, Talassi

, Tomasini

G.L.

, Fato

, Estornell

, Lucarini

, Lenaz

, Simonelli

, Brunelli

M.A.

, Biagini

. Gingival fibroblasts “in vitro” and Down's Syndrome.

doi: 10.1007/BF00746056

Prince

, Jia

, Båve

, Annerén

, Oreland

. Mitochondrial enzyme deficiencies in Down's syndrome.

doi: 10.1007/BF02260938

Kim

S.H.

, Vlkolinsky

, Cairns

, Lubec

. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome.

doi: 10.1007/pl00000661

Kim

S.H.

, Fountoulakis

, Dierssen

, Lubec

. Decreased protein levels of complex I 30-kDa subunit in fetal Down syndrome brains.

109–16

doi: 10.1007/978-3-7091-6262-0_9

Kim

S.H.

, Vlkolinsky

, Cairns

, Fountoulakis

, Lubec

. The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease.

doi: 10.1016/s0024-3205(01)01074-8

Liu

, Borel

, Li

, Müller

, Williams

E.G.

, Germain

P.-L.

, Buljan

, Sajic

, Boersema

P.J.

, Shao

, Faini

, Testa

, Beyer

, Antonarakis

S.E.

, Aebersold

. Systematic proteome and proteostasis profiling in human Trisomy 21 fibroblast cells.

doi: 10.1038/s41467-017-01422-6

Tiano

, Padella

, Carnevali

, Gabrielli

, Bruge

, Principi

, Littarru

G.P.

. Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects.

doi: 10.1002/biof.5520320119

M.E. Zaki, H.T. El-Bassyouni, A.M.S. Tosson, E. Youness, J. Hussein, Coenzyme Q10 and pro-inflammatory markers in children with Down syndrome: clinical and biochemical aspects., J. Pediatr. 93 (n.d.) 100–104. 10.1016/j.jped.2016.04.012.

Qiu

J.-J.

, Liu

Y.-N.

, Ren

Z.-R.

, Yan

J.-B.

. Dysfunctions of mitochondria in close association with strong perturbation of long noncoding RNAs expression in down syndrome.

doi: 10.1016/j.biocel.2017.09.017

Krapfenbauer

, Yoo

B.C.

, Cairns

, Lubec

. Differential display reveals deteriorated mRNA levels of NADH3 (complex I) in cerebellum of patients with Down syndrome.

doi: 10.1007/978-3-7091-6380-1_13

Salemi

, Giambirtone

, Barone

, Salluzzo

M.G.

, Russo

, Lo Giudice

, Cutuli

, Ridolfo

, Romano

. Mitochondrial mRNA expression in fibroblasts of Down syndrome subjects.

doi: 10.1007/s13577-018-0205-2

Lee

S.H.

, Lee

, Jun

H.S.

, Jeong

H.J.

, Cha

W.T.

, Cho

Y.S.

, Kim

J.H.

, Ku

S.Y.

, Cha

K.Y.

. Expression of the mitochondrial ATPase6 gene and Tfam in Down syndrome.

Conti

, Fabbrini

, D'Agostino

, Negri

, Greco

, Genesio

, D'Armiento

, Olla

, Paladini

, Zannini

, Nitsch

. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy.

doi: 10.1186/1471-2164-8-268

Chang

K.T.

, Min

K.-T.

. Drosophila melanogaster homolog of Down syndrome critical region 1 is critical for mitochondrial function.

doi: 10.1038/nn1564

Coskun

P.E.

, Wyrembak

, Derbereva

, Melkonian

, Doran

, Lott

I.T.

, Head

, Cotman

C.W.

, Wallace

D.C.

. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia.

Suppl 2

doi: 10.3233/JAD-2010-100351

Sobol

, Klar

, Laan

, Shahsavani

, Schuster

, Annerén

, Konzer

, Mi

, Bergquist

, Nordlund

, Hoeber

, Huss

, Falk

, Dahl

. Transcriptome and proteome profiling of neural induced pluripotent stem cells from individuals with down syndrome disclose dynamic dysregulations of key pathways and cellular functions.

doi: 10.1007/s12035-019-1585-3

Phillips

A.C.

, Sleigh

, McAllister

C.J.

, Brage

, Carpenter

T.A.

, Kemp

G.J.

, Holland

A.J.

. Defective mitochondrial function in vivo in skeletal muscle in adults with Down's syndrome: a 31P-MRS study.

e84031

doi: 10.1371/journal.pone.0084031

Pecze

, Randi

E.B.

, Szabo

. Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome.

doi: 10.1186/s10020-020-00225-8

McCormick

E.M.

, Lott

M.T.

, Dulik

M.C.

, Shen

, Attimonelli

, Vitale

, Karaa

, Bai

, Pineda-Alvarez

D.E.

, Singh

L.N.

, Stanley

C.M.

, Wong

, Bhardwaj

, Merkurjev

, Mao

, Sondheimer

, Zhang

, Procaccio

, Wallace

D.C.

, Gai

, Falk

M.J.

. Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretation.

doi: 10.1002/humu.24107

Haas

R.H.

, Parikh

, Falk

M.J.

, Saneto

R.P.

, Wolf

N.I.

, Darin

, Cohen

B.H.

. Mitochondrial disease: a practical approach for primary care physicians.

doi: 10.1542/peds.2007-0391

Zolkipli-Cunningham

, Xiao

, Stoddart

, McCormick

E.M.

, Holberts

, Burrill

, McCormack

, Williams

, Wang

, Thompson

J.L.P.

, Falk

M.J.

. Mitochondrial disease patient motivations and barriers to participate in clinical trials.

e0197513

doi: 10.1371/journal.pone.0197513

Courchesne

, Gazestani

V.H.

, Lewis

N.E.

. Prenatal origins of ASD: the when, what, and how of ASD development.

doi: 10.1016/j.tins.2020.03.005

Giulivi

, Zhang

Y.-F.

, Omanska-Klusek

, Ross-Inta

, Wong

, Hertz-Picciotto

, Tassone

, Pessah

I.N.

. Mitochondrial dysfunction in autism.

doi: 10.1001/jama.2010.1706

Rossignol

D.A.

, Frye

R.E.

. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis.

doi: 10.1038/mp.2010.136

Sullivan

K.D.

, Lewis

H.C.

, Hill

A.A.

, Pandey

, Jackson

L.P.

, Cabral

J.M.

, Smith

K.P.

, Liggett

L.A.

, Gomez

E.B.

, Galbraith

M.D.

, DeGregori

, Espinosa

J.M.

. Trisomy 21 consistently activates the interferon response.

doi: 10.7554/eLife.16220

Gonzales

P.K.

, Roberts

C.M.

, Fonte

, Jacobsen

, Stein

G.H.

, Link

C.D.

. Transcriptome analysis of genetically matched human induced pluripotent stem cells disomic or trisomic for chromosome 21.

e0194581

doi: 10.1371/journal.pone.0194581

Briggs

J.A.

, Sun

, Shepherd

, Ovchinnikov

D.A.

, Chung

T.-L.

, Nayler

S.P.

, Kao

L.-P.

, Morrow

C.A.

, Thakar

N.Y.

, Soo

S.-Y.

, Peura

, Grimmond

, Wolvetang

E.J.

. Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology.

doi: 10.1002/stem.1297

H.-E.

, Yang

Y.-C.

, Chen

S.-M.

, Su

H.-L.

, Huang

P.-C.

, Tsai

M.-S.

, Wang

T.-H.

, Tseng

C.-P.

, Hwang

S.-M.

. Modeling neurogenesis impairment in Down syndrome with induced pluripotent stem cells from Trisomy 21 amniotic fluid cells.

doi: 10.1016/j.yexcr.2012.09.017

Ponroy Bally

, Farmer

W.T.

, V Jones

, Jessa

, Kacerovsky

J.B.

, Mayran

, Peng

, Lefebvre

J.L.

, Drouin

, Hayer

, Ernst

, Murai

K.K.

. Human iPSC-derived Down syndrome astrocytes display genome-wide perturbations in gene expression, an altered adhesion profile, and increased cellular dynamics.

doi: 10.1093/hmg/ddaa003

Tanzi

R.E.

, Gusella

J.F.

, Watkins

P.C.

, Bruns

G.A.

, St George-Hyslop

, Van Keuren

M.L.

, Patterson

, Pagan

, Kurnit

D.M.

, Neve

R.L.

. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.

doi: 10.1126/science.2949367

Tanzi

R.E.

, Haines

J.L.

, Watkins

P.C.

, Stewart

G.D.

, Wallace

M.R.

, Hallewell

, Wong

, Wexler

N.S.

, Conneally

P.M.

, Gusella

J.F.

. Genetic linkage map of human chromosome 21.

doi: 10.1016/0888-7543(88)90143-7

Sosa

L.J.

, Postma

N.L.

, Estrada-Bernal

, Hanna

, Guo

, Busciglio

, Pfenninger

K.H.

. Dosage of amyloid precursor protein affects axonal contact guidance in Down syndrome.

doi: 10.1096/fj.13-232686

El Hajj

, Dittrich

, Böck

, Kraus

T.F.J.

, Nanda

, Müller

, Seidmann

, Tralau

, Galetzka

, Schneider

, Haaf

. Epigenetic dysregulation in the developing Down syndrome cortex.

doi: 10.1080/15592294.2016.1192736

Guedj

, LA Pennings

, Massingham

L.J.

, Wick

H.C.

, Siegel

A.E.

, Tantravahi

, Bianchi

D.W.

. An integrated human/murine transcriptome and pathway approach to identify prenatal treatments for down syndrome.

32353

doi: 10.1038/srep32353

Teller

J.K.

, Russo

, DeBusk

L.M.

, Angelini

, Zaccheo

, Dagna-Bricarelli

, Scartezzini

, Bertolini

, Mann

D.M.

, Tabaton

, Gambetti

. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome.

doi: 10.1038/nm0196-93

Russo

, Salis

, Dolcini

, Venezia

, Song

X.H.

, Teller

J.K.

, Schettini

. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.

doi: 10.1006/nbdi.2000.0357

Wilkins

H.M.

, Swerdlow

R.H.

. Amyloid precursor protein processing and bioenergetics.

doi: 10.1016/j.brainresbull.2016.08.009

Lopez Sanchez

M.I.G.

, van Wijngaarden

, Trounce

I.A.

. Amyloid precursor protein-mediated mitochondrial regulation and Alzheimer's disease.

doi: 10.1111/bph.14554

Chadefaux

, Rethoré

M.O.

, Raoul

, Ceballos

, Poissonnier

, Gilgenkranz

, Allard

. Cystathionine beta synthase: gene dosage effect in trisomy 21.

doi: 10.1016/0006-291x(85)91641-9

Taub

J.W.

, Huang

, Matherly

L.H.

, Stout

M.L.

, Buck

S.A.

, V Massey

, Becton

D.L.

, Chang

M.N.

, Weinstein

H.J.

, Ravindranath

. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.

, Jensen

T.L.

, Matherly

L.H.

, Taub

J.W.

. Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines.

doi: 10.1182/blood-2002-07-2337

Ichinohe

, Kanaumi

, Takashima

, Enokido

, Nagai

, Kimura

. Cystathionine beta-synthase is enriched in the brains of Down's patients.

doi: 10.1016/j.bbrc.2005.10.118

Lockstone

H.E.

, Harris

L.W.

, Swatton

J.E.

, Wayland

M.T.

, Holland

A.J.

, Bahn

. Gene expression profiling in the adult Down syndrome brain.

doi: 10.1016/j.ygeno.2007.08.005

E. Abdel-Salam, M. Aboul-Enein, A. Kotb, M. Elseify, A. Abul-Hassan, S. Ishaac, Hematologic changes in Down's syndrome during infantile and early childhood period., Gaz. Egypt Paediatr. Assoc. 24 (n.d.) 209–16. http://www.ncbi.nlm.nih.gov/pubmed/145981.

Pinilla

J.M.

, Ayala-Ramírez

, García-Robles

, Olaya-C

, Bermúdez

. Expression of cystathionine beta-synthase and histopathological observations in placentas of patients with Down syndrome.

doi: 10.3233/NPM-15814092

Olmos-Serrano

J.L.

, Kang

H.J.

, Tyler

W.A.

, Silbereis

J.C.

, Cheng

, Zhu

, Pletikos

, Jankovic-Rapan

, Cramer

N.P.

, Galdzicki

, Goodliffe

, Peters

, Sethares

, Delalle

, Golden

J.A.

, Haydar

T.F.

, Sestan

. Down syndrome developmental brain transcriptome reveals defective oligodendrocyte differentiation and myelination.

doi: 10.1016/j.neuron.2016.01.042

Szabo

. The re-emerging pathophysiological role of the cystathionine-β-synthase - hydrogen sulfide system in Down syndrome.

doi: 10.1111/febs.15214

Benson

P.F.

, Linacre

, Taylor

A.I.

. Erythrocyte ATP: D-fructose-6-phosphate 1-phosphotransferase (phosphofructokinase) activity in children with normałG trisomic mosaic Down's syndrome and in normal and Down's syndrome controls.

doi: 10.1038/2201235a0

Pantelakis

S.N.

, Karaklis

A.G.

, Alexiou

, Vardas

, Valaes

. Red cell enzymes in trisomy 21.

Annerén

K.G.

, Korenberg

J.R.

, Epstein

C.J.

. Phosphofructokinase activity in fibroblasts aneuploid for chromosome 21.

doi: 10.1007/BF00283052

Zhang

, Qian

, Qin

, Lin

, Wu

, Chang

, Luo

, Zhu

. Phosphofructokinase-1 negatively regulates neurogenesis from neural stem cells.

doi: 10.1007/s12264-016-0032-y

Kobayashi

, Hatakeyama

, Nishimura

, Yokota

, Suzuki

, Tomabechi

, Shirouzu

, Osada

, Mimaki

, Goto

Y.-I.

, Yoshida

. Chemical reversal of abnormalities in cells carrying mitochondrial DNA mutations.

doi: 10.1038/s41589-020-00676-4

Tlili

, Hoischen

, Ripoll

, Benabou

, Badel

, Ronan

, Touraine

, Grattau

, Stora

, van Bon

, de Vries

, Menten

, Bockaert

, Gecz

, Antonarakis

S.E.

, Campion

, Potier

M.-C.

, Bléhaut

, Delabar

J.-M.

, Janel

. BDNF and DYRK1A are variable and inversely correlated in lymphoblastoid cell lines from Down syndrome patients.

doi: 10.1007/s12035-012-8284-7

Granese

, Scala

, Spatuzza

, Valentino

, Coletta

, Vacca

R.A.

, De Luca

, Andria

. Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome.

doi: 10.1186/1755-8794-6-24

100

Dowjat

W.K.

, Adayev

, Kuchna

, Nowicki

, Palminiello

, Hwang

Y.W.

, Wegiel

. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.

doi: 10.1016/j.neulet.2006.11.026

101

Liu

, Liang

, Wegiel

, Hwang

Y.-W.

, Iqbal

, Grundke-Iqbal

, Ramakrishna

, Gong

C.-X.

. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.

doi: 10.1096/fj.07-104539

102

Shi

, Zhang

, Zhou

, Chohan

M.O.

, Gu

, Wegiel

, Zhou

, Hwang

Y.-W.

, Iqbal

, Grundke-Iqbal

, Gong

C.-X.

, Liu

. Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome.

doi: 10.1074/jbc.M802645200

103

Wegiel

, Kaczmarski

, Barua

, Kuchna

, Nowicki

, Wang

K.-C.

, Wegiel

, Yang

S.M.

, Frackowiak

, Mazur-Kolecka

, Silverman

W.P.

, Reisberg

, Monteiro

, de Leon

, Wisniewski

, Dalton

, Lai

, Hwang

Y.-W.

, Adayev

, Liu

, Iqbal

I.-G.

, Gong

C.-X.

. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.

doi: 10.1097/NEN.0b013e318202bfa1

104

Guimera

, Casas

, Estivill

, Pritchard

. Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome.

doi: 10.1006/geno.1999.5775

105

Kim

M.-Y.

, Jeong

B.C.

, Lee

J.H.

, Kee

H.J.

, Kook

, Kim

N.S.

, Kim

Y.H.

, Kim

J.-K.

, Ahn

K.Y.

, Kim

K.K.

. A repressor complex, AP4 transcription factor and geminin, negatively regulates expression of target genes in nonneuronal cells.

doi: 10.1073/pnas.0601915103

106

Arron

J.R.

, Winslow

M.M.

, Polleri

, Chang

C.-P.

, Wu

, Gao

, Neilson

J.R.

, Chen

, Heit

J.J.

, Kim

S.K.

, Yamasaki

, Miyakawa

, Francke

, Graef

I.A.

, Crabtree

G.R.

. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21.

doi: 10.1038/nature04678

107

Handschin

, Rhee

, Lin

, Tarr

P.T.

, Spiegelman

B.M.

. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle.

doi: 10.1073/pnas.1232352100

108

Ventura-Clapier

, Garnier

, Veksler

. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha.

doi: 10.1093/cvr/cvn098

109

Altug-Teber

, Bonin

, Walter

, Mau-Holzmann

U.A.

, Dufke

, Stappert

, Tekesin

, Heilbronner

, Nieselt

, Riess

. Specific transcriptional changes in human fetuses with autosomal trisomies.

doi: 10.1159/000112058

110

Volk

, Maver

, Lovrečić

, Juvan

, Peterlin

. Expression signature as a biomarker for prenatal diagnosis of trisomy 21.

e74184

doi: 10.1371/journal.pone.0074184

111

Gimeno

, García-Giménez

J.L.

, Audí

, Toran

, Andaluz

, Dasí

, Viña

, V Pallardó

. Decreased cell proliferation and higher oxidative stress in fibroblasts from Down Syndrome fetuses. Preliminary study.

doi: 10.1016/j.bbadis.2013.10.014

112

Baek

K.-H.

, Zaslavsky

, Lynch

R.C.

, Britt

, Okada

, Siarey

R.J.

, Lensch

M.W.

, Park

I.-H.

, Yoon

S.S.

, Minami

, Korenberg

J.R.

, Folkman

, Daley

G.Q.

, Aird

W.C.

, Galdzicki

, Ryeom

. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.

doi: 10.1038/nature08062

113

Fuentes

J.J.

, Genescà

, Kingsbury

T.J.

, Cunningham

K.W.

, Pérez-Riba

, Estivill

, de la Luna

. DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways.

doi: 10.1093/hmg/9.11.1681

114

Dashinimaev

E.B.

, Artyuhov

A.S.

, Bolshakov

A.P.

, Vorotelyak

E.A.

, V Vasiliev

. Neurons derived from induced pluripotent stem cells of patients with down syndrome reproduce early stages of alzheimer's disease type pathology in vitro.

doi: 10.3233/JAD-160945

115

Ermak

, Sojitra

, Yin

, Cadenas

, Cuervo

A.M.

, Davies

K.J.A.

. Chronic expression of RCAN1-1L protein induces mitochondrial autophagy and metabolic shift from oxidative phosphorylation to glycolysis in neuronal cells.

doi: 10.1074/jbc.M111.305342

116

Peiris

, Duffield

M.D.

, Fadista

, Jessup

C.F.

, Kashmir

, Genders

A.J.

, McGee

S.L.

, Martin

A.M.

, Saiedi

, Morton

, Carter

, Cousin

M.A.

, Kokotos

A.C.

, Oskolkov

, Volkov

, Hough

T.A.

, Fisher

E.M.C.

, Tybulewicz

V.L.J.

, Busciglio

, Coskun

P.E.

, Becker

, V Belichenko

, Mobley

W.C.

, Ryan

M.T.

, Chan

J.Y.

, Laybutt

D.R.

, Coates

P.T.

, Yang

, Ling

, Groop

, Pritchard

M.A.

, Keating

D.J.

. A syntenic cross species aneuploidy genetic screen links RCAN1 expression to β-cell mitochondrial dysfunction in type 2 diabetes.

e1006033

doi: 10.1371/journal.pgen.1006033

117

Sun

, Hao

, An

, Li

, Xi

, Shen

. Overexpression of Rcan1-1L inhibits hypoxia-induced cell apoptosis through induction of mitophagy.

doi: 10.14348/molcells.2014.0103

118

Yan

, Yang

, Li

, Duan

, Wu

, Qian

, Li

, Wang

. Regulator of calcineurin 1-1L protects cardiomyocytes against hypoxia-induced apoptosis via mitophagy.

doi: 10.1097/FJC.0000000000000121

119

Lim

, Hwang

, Yu

J.H.

, Lim

J.W.

, Kim

. Lycopene inhibits regulator of calcineurin 1-mediated apoptosis by reducing oxidative stress and down-regulating Nucling in neuronal cells.

doi: 10.1002/mnfr.201600530

120

Izzo

, Manco

, Bonfiglio

, Calì

, De Cristofaro

, Patergnani

, Cicatiello

, Scrima

, Zannini

, Pinton

, Conti

, Nitsch

. NRIP1/RIP140 siRNA-mediated attenuation counteracts mitochondrial dysfunction in Down syndrome.

doi: 10.1093/hmg/ddu157

121

Wang

, Ren

, Yu

, Mu

, Ye

, Cui

, Guo

. Cognitive impairments in adult mice with RIP140 overexpression in neural stem cells.

doi: 10.1016/j.bbr.2020.112777

122

Leonardsson

, Steel

J.H.

, Christian

, Pocock

, Milligan

, Bell

, So

P.-W.

, Medina-Gomez

, Vidal-Puig

, White

, Parker

M.G.

. Nuclear receptor corepressor RIP140 regulates fat accumulation.

doi: 10.1073/pnas.0401013101

123

Powelka

A.M.

, Seth

, V Virbasius

, Kiskinis

, Nicoloro

S.M.

, Guilherme

, Tang

, Straubhaar

, Cherniack

A.D.

, Parker

M.G.

, Czech

M.P.

. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes.

doi: 10.1172/JCI26040

124

Haden

D.W.

, Suliman

H.B.

, Carraway

M.S.

, Welty-Wolf

K.E.

, Ali

A.S.

, Shitara

, Yonekawa

, Piantadosi

C.A.

. Mitochondrial biogenesis restores oxidative metabolism during Staphylococcus aureus sepsis.

doi: 10.1164/rccm.200701-161OC

125

Puri

, Chakladar

, V Virbasius

, Konda

, Powelka

A.M.

, Chouinard

, Hagan

G.N.

, Perugini

, Czech

M.P.

. RNAi-based gene silencing in primary mouse and human adipose tissues.

doi: 10.1194/jlr.D600033-JLR200

126

Seth

, Steel

J.H.

, Nichol

, Pocock

, Kumaran

M.K.

, Fritah

, Mobberley

, Ryder

T.A.

, Rowlerson

, Scott

, Poutanen

, White

, Parker

. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle.

doi: 10.1016/j.cmet.2007.08.004

127

Williams

D.B.

, Sutherland

L.N.

, Bomhof

M.R.

, Basaraba

S.A.U.

, Thrush

A.B.

, Dyck

D.J.

, Field

C.J.

, Wright

D.C.

. Muscle-specific differences in the response of mitochondrial proteins to beta-GPA feeding: an evaluation of potential mechanisms.

doi: 10.1152/ajpendo.90913.2008

128

Fritah

, Steel

J.H.

, Nichol

, Parker

, Williams

, Price

, Strauss

, Ryder

T.A.

, Mobberley

M.A.

, Poutanen

, Parker

, White

. Elevated expression of the metabolic regulator receptor-interacting protein 140 results in cardiac hypertrophy and impaired cardiac function.

doi: 10.1093/cvr/cvp418

129

Chen

, Wang

, Chen

, Cao

, Chen

, Xu

, Huang

, Liu

. Roles of transcriptional corepressor RIP140 and coactivator PGC-1α in energy state of chronically infarcted rat hearts and mitochondrial function of cardiomyocytes.

doi: 10.1016/j.mce.2012.03.023

130

Hoshino

, Yoshida

, Holloway

G.P.

, Lally

, Hatta

, Bonen

. Clenbuterol, a β2-adrenergic agonist, reciprocally alters PGC-1 alpha and RIP140 and reduces fatty acid and pyruvate oxidation in rat skeletal muscle.

doi: 10.1152/ajpregu.00183.2011

131

Furrer

, DE Haan

, Bravenboer

, Kos

, Lips

, Jaspers

R.T.

. Effects of concurrent training on oxidative capacity in rat gastrocnemius muscle.

doi: 10.1249/MSS.0b013e31828fc65f

132

Zhang

, Chen

, Yue

, He

, Zou

, Chen

, Liu

, Chen

, Liu

, Feng

, Li

, Liu

. The p65 subunit of NF-κB involves in RIP140-mediated inflammatory and metabolic dysregulation in cardiomyocytes.

doi: 10.1016/j.abb.2014.05.005

133

Herbst

E.A.F.

, Bonen

, Holloway

G.P.

. Changes in nuclear receptor corepressor RIP140 do not influence mitochondrial content in the cortex.

doi: 10.1139/apnm-2015-0192

134

Miotto

P.M.

, Frendo-Cumbo

, Sacco

S.M.

, Wright

D.C.

, Ward

W.E.

, Holloway

G.P.

. Combined high-fat-resveratrol diet and RIP140 knockout mice reveal a novel relationship between elevated bone mitochondrial content and compromised bone microarchitecture, bone mineral mass, and bone strength in the tibia.

1994–2007

doi: 10.1002/mnfr.201500870

135

Chen

, Chen

, Yue

, Zhang

, Zhou

, Cao

, Chen

, Zhang

, Liu

. Receptor-interacting protein 140 overexpression impairs cardiac mitochondrial function and accelerates the transition to heart failure in chronically infarcted rats.

doi: 10.1016/j.trsl.2016.08.005

136

You

, Yue

, Chen

, Lu

, Zhang

, Shen

, Li

, Han

, Li

, Liu

. Receptor-interacting Protein 140 represses Sirtuin 3 to facilitate hypertrophy, mitochondrial dysfunction and energy metabolic dysfunction in cardiomyocytes.

doi: 10.1111/apha.12800

137

Park

S.-S.

, Lee

Y.-J.

, Kang

, Yang

, Hong

E.J.

, Lim

J.Y.

, Oh

, Kim

. Lactobacillus amylovorus KU4 ameliorates diet-induced obesity in mice by promoting adipose browning through PPARγ signaling.

20152

doi: 10.1038/s41598-019-56817-w

138

Birket

M.J.

, Orr

A.L.

, Gerencser

A.A.

, Madden

D.T.

, Vitelli

, Swistowski

, Brand

M.D.

, Zeng

. A reduction in ATP demand and mitochondrial activity with neural differentiation of human embryonic stem cells.

doi: 10.1242/jcs.072272

139

Sánchez-Font

M.F.

, Bosch-Comas

, Gonzàlez-Duarte

, Marfany

. Overexpression of FABP7 in Down syndrome fetal brains is associated with PKNOX1 gene-dosage imbalance.

doi: 10.1093/nar/gkg396

140

Micali

, Longobardi

, Iotti

, Ferrai

, Castagnaro

, Ricciardi

, Blasi

, Crippa

M.P.

. Down syndrome fibroblasts and mouse Prep1-overexpressing cells display increased sensitivity to genotoxic stress.

doi: 10.1093/nar/gkq019

141

Kanzleiter

, Rath

, Penkov

, Puchkov

, Schulz

, Blasi

, Schürmann

. Pknox1/Prep1 regulates mitochondrial oxidative phosphorylation components in skeletal muscle.

doi: 10.1128/MCB.01232-13

142

You

S.-H.

, Lee

Y.-S.

, Chang

Y.-J.

, Lin

C.-Y.

, Wang

T.-H.

, Chang

Y.-L.

. Gene expression profiling of amniotic fluid mesenchymal stem cells of monozygotic twins discordant for trisomy 21.

144461

doi: 10.1016/j.gene.2020.144461

143

Ferrando-Miguel

, Cheon

M.S.

, Yang

J.W.

, Lubec

. Overexpression of transcription factor BACH1 in fetal Down syndrome brain.

doi: 10.1007/978-3-7091-6721-2_17

144

Lee

, Yesilkanal

A.E.

, Wynne

J.P.

, Frankenberger

, Liu

, Yan

, Elbaz

, Rabe

D.C.

, Rustandy

F.D.

, Tiwari

, Grossman

E.A.

, Hart

P.C.

, Kang

, Sanderson

S.M.

, Andrade

, Nomura

D.K.

, Bonini

M.G.

, Locasale

J.W.

, Rosner

M.R.

. Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism.

doi: 10.1038/s41586-019-1005-x

145

St-Pierre

, Drori

, Uldry

, Silvaggi

J.M.

, Rhee

, Jäger

, Handschin

, Zheng

, Lin

, Yang

, Simon

D.K.

, Bachoo

, Spiegelman

B.M.

. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators.

doi: 10.1016/j.cell.2006.09.024

146

Mollo

, Cicatiello

, Aurilia

, Scognamiglio

, Genesio

, Charalambous

, Paladino

, Conti

, Nitsch

, Izzo

. Targeting mitochondrial network architecture in down syndrome and aging.

doi: 10.3390/ijms21093134

147

Guedj

, Bianchi

D.W.

, Delabar

J.-M.

. Prenatal treatment of Down syndrome: a reality?.

doi: 10.1097/GCO.0000000000000056

148

Stagni

, Giacomini

, Guidi

, Ciani

, Bartesaghi

. Timing of therapies for Down syndrome: the sooner, the better.

doi: 10.3389/fnbeh.2015.00265

149

Jia

, Wang

, Cao

, Zhang

, Rong

, Xu

. Activation of PGC-1α and mitochondrial biogenesis protects against prenatal hypoxic-ischemic brain injury.

doi: 10.1016/j.neuroscience.2020.02.035

150

Vacca

R.A.

, Valenti

, Caccamese

, Daglia

, Braidy

, Nabavi

S.M.

. Plant polyphenols as natural drugs for the management of Down syndrome and related disorders.

doi: 10.1016/j.neubiorev.2016.10.023

151

Valenti

, Braidy

, De Rasmo

, Signorile

, Rossi

, Atanasov

A.G.

, Volpicella

, Henrion-Caude

, Nabavi

S.M.

, Vacca

R.A.

. Mitochondria as pharmacological targets in Down syndrome.

doi: 10.1016/j.freeradbiomed.2017.08.014

152

Vacca

R.A.

, Bawari

, Valenti

, Tewari

, Nabavi

S.F.

, Shirooie

, Sah

A.N.

, Volpicella

, Braidy

, Nabavi

S.M.

. Down syndrome: neurobiological alterations and therapeutic targets.

doi: 10.1016/j.neubiorev.2019.01.001

153

Zuhra

, Augsburger

, Majtan

, Szabo

. Cystathionine-β-Synthase: molecular regulation and pharmacological inhibition.

doi: 10.3390/biom10050697

154

Feki

, Hibaoui

. DYRK1A protein, A promising therapeutic target to improve cognitive deficits in down syndrome.

doi: 10.3390/brainsci8100187

155

Chaturvedi

R.K.

, Calingasan

N.Y.

, Yang

, Hennessey

, Johri

, Beal

M.F.

. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

doi: 10.1093/hmg/ddq229

156

Vaughan

R.A.

, Garcia-Smith

, Bisoffi

, Trujillo

K.A.

, Conn

C.A.

. Effects of caffeine on metabolism and mitochondria biogenesis in rhabdomyosarcoma cells compared with 2,4-dinitrophenol.

doi: 10.4137/NMI.S10233

157

Shi

, Li

, Ding

, Yang

, Chen

, Fan

, Jiang

, Guan

, Liu

, Xu

, Wu

. The critical role of epigallocatechin gallate in regulating mitochondrial metabolism.

doi: 10.4155/fmc-2017-0204

158

Ruiz-Pesini

, Emperador

, López-Gallardo

, Hernández-Ainsa

, Montoya

. Increasing mtDNA levels as therapy for mitochondrial optic neuropathies.

doi: 10.1016/j.drudis.2018.01.031

159

Arbones

M.L.

, Thomazeau

, Nakano-Kobayashi

, Hagiwara

, Delabar

J.M.

. DYRK1A and cognition: a lifelong relationship.

doi: 10.1016/j.pharmthera.2018.09.010

160

Zhang

J.-C.

, Xu

, Yuan

, Chen

J.-Y.

, Zhang

Y.-J.

, Lin

, Yuan

S.-Y.

. Delayed treatment with green tea polyphenol EGCG promotes neurogenesis after ischemic stroke in adult mice.

doi: 10.1007/s12035-016-9924-0

161

Stagni

, Giacomini

, Emili

, Trazzi

, Guidi

, Sassi

, Ciani

, Rimondini

, Bartesaghi

. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.

doi: 10.1016/j.neuroscience.2016.07.031

162

Souchet

, Duchon

, Gu

, Dairou

, Chevalier

, Daubigney

, Nalesso

, Créau

, Yu

, Janel

, Herault

, Delabar

J.M.

. Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models.

doi: 10.1038/s41598-019-40328-9

163

Vacca

R.A.

, Valenti

. Green tea EGCG plus fish oil omega-3 dietary supplements rescue mitochondrial dysfunctions and are safe in a Down's syndrome child.

doi: 10.1016/j.clnu.2015.04.012

164

Lee

M.-S.

, Shin

, Moon

, Kim

. Effects of eicosapentaenoic acid and docosahexaenoic acid on mitochondrial DNA replication and PGC-1α gene expression in C2C12 muscle cells.

doi: 10.3746/pnf.2016.21.4.317

165

Zmijewski

P.A.

, Gao

L.Y.

, Saxena

A.R.

, Chavannes

N.K.

, Hushmendy

S.F.

, Bhoiwala

D.L.

, Crawford

D.R.

. Fish oil improves gene targets of Down syndrome in C57BL and BALB/c mice.

doi: 10.1016/j.nutres.2015.02.007

166

Zhou

, Wu

, Chen

, Wang

. AMP-activated protein kinase is required for the anti-adipogenic effects of alpha-linolenic acid.

doi: 10.1186/s12986-015-0006-5

167

You

, Fan

, Kim

, Shin

S.-H.

, Chung

. Alpha-linolenic acid-enriched butter promotes fatty acid remodeling and thermogenic activation in the Brown adipose tissue.

doi: 10.3390/nu12010136

168

Litwiniuk

, Domańska

, Chmielowska

, Martyńska

, Bik

, Kalisz

. The effects of alpha-linolenic acid on the secretory activity of astrocytes and β amyloid-associated neurodegeneration in differentiated SH-SY5Y cells: alpha-linolenic acid protects the SH-SY5Y cells against β amyloid toxicity.

8908901

doi: 10.1155/2020/8908901

169

García-Cerro

, Rueda

, Vidal

, Puente

, Campa

, Lantigua

, Narcís

, Velasco

, Bartesaghi

, Martínez-Cué

. Prenatal administration of oleic acid or linolenic acid reduces neuromorphological and cognitive alterations in Ts65dn down syndrome mice.

doi: 10.1093/jn/nxaa074

170

Niculescu

M.D.

, Lupu

D.S.

, Craciunescu

C.N.

. Maternal α-linolenic acid availability during gestation and lactation alters the postnatal hippocampal development in the mouse offspring.

doi: 10.1016/j.ijdevneu.2011.09.006

171

Ljubicic

, Jasmin

B.J.

. Metformin increases peroxisome proliferator-activated receptor γ Co-activator-1α and utrophin a expression in dystrophic skeletal muscle.

doi: 10.1002/mus.24692

172

Karnewar

, Neeli

P.K.

, Panuganti

, Kotagiri

, Mallappa

, Jain

, Jerald

M.K.

, Kotamraju

. Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: relevance in age-associated vascular dysfunction.

doi: 10.1016/j.bbadis.2018.01.018

173

Ahn

M.-J.

, Cho

G.-W.

. Metformin promotes neuronal differentiation and neurite outgrowth through AMPK activation in human bone marrow-mesenchymal stem cells.

doi: 10.1002/bab.1584

174

Gureev

A.P.

, Shaforostova

E.A.

, Starkov

A.A.

, Popov

V.N.

. β-Guanidinopropionic acid stimulates brain mitochondria biogenesis and alters cognitive behavior in nondiseased mid-age mice.

doi: 10.1177/1179069518766524

175

Ahuja

, Ammal Kaidery

, Yang

, Calingasan

, Smirnova

, Gaisin

, Gaisina

I.N.

, Gazaryan

, Hushpulian

D.M.

, Kaddour-Djebbar

, Bollag

W.B.

, Morgan

J.C.

, Ratan

R.R.

, Starkov

A.A.

, Beal

M.F.

, Thomas

. Distinct Nrf2 signaling mechanisms of fumaric acid esters and their role in neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced experimental Parkinson’s-like disease.

doi: 10.1523/JNEUROSCI.0426-16.2016

176

Guidi

, Stagni

, Bianchi

, Ciani

, Giacomini

, De Franceschi

, Moldrich

, Kurniawan

, Mardon

, Giuliani

, Calzà

, Bartesaghi

. Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.

doi: 10.1093/brain/awt340

177

Guedj

, Siegel

A.E.

, Pennings

J.L.A.

, Alsebaa

, Massingham

L.J.

, Tantravahi

, Bianchi

D.W.

. Apigenin as a candidate prenatal treatment for trisomy 21: effects in human amniocytes and the Ts1Cje mouse model.

doi: 10.1016/j.ajhg.2020.10.001

178

Rueda

, Vidal

, García-Cerro

, Puente

, Campa

, Lantigua

, Narcís

, Bartesaghi

, Martínez-Cué

. Prenatal, but not postnatal, curcumin administration rescues neuromorphological and cognitive alterations in Ts65Dn down syndrome mice.

doi: 10.1093/jn/nxaa207

179

Liu

, Zhang

, Wang

, Li

, Tan

, Lu

, Deng

, Zhang

, Guo

, Mu

, Yu

. Curcumin prevents cerebral ischemia reperfusion injury via increase of mitochondrial biogenesis.

doi: 10.1007/s11064-014-1315-1

180

Trujillo

, Granados-Castro

L.F.

, Zazueta

, Andérica-Romero

A.C.

, Chirino

Y.I.

, Pedraza-Chaverrí

. Mitochondria as a target in the therapeutic properties of curcumin.

doi: 10.1002/ardp.201400266

181

de Oliveira

M.R.

, Jardim

F.R.

, Setzer

W.N.

, Nabavi

S.M.

, Nabavi

S.F.

. Curcumin, mitochondrial biogenesis, and mitophagy: exploring recent data and indicating future needs.

doi: 10.1016/j.biotechadv.2016.04.004

182

Choi

W.H.

, Son

H.J.

, Jang

Y.J.

, Ahn

, Jung

C.H.

, Ha

T.Y.

. Apigenin ameliorates the obesity‐induced skeletal muscle atrophy by attenuating mitochondrial dysfunction in the muscle of obese mice.

1700218

doi: 10.1002/mnfr.201700218

183

Barros

M. da L.D.

, Manhães-de-Castro

, Alves

D.T.

, Quevedo

O.G.

, Toscano

A.E.

, Bonnin

, Galindo

. Long term effects of neonatal exposure to fluoxetine on energy balance: a systematic review of experimental studies.

doi: 10.1016/j.ejphar.2018.06.013

184

Simões‐Alves

A.C.

, Silva‐Filho

R.C.

, Braz

G.R.F.

, Silva

S.C.A.

, da Silva

A.I.

, Lagranha

C.J.

, Fernandes

M.P.

. Neonatal treatment with fluoxetine improves mitochondrial respiration and reduces oxidative stress in liver of adult rats.

doi: 10.1002/jcb.26758

185

Braz

G.R.F.

, Silva

S.C. de A.

, Pedroza

A.A. da S.

, de Lemos

M.D.

, de Lima

F.A.

, da Silva

A.I.

, Lagranha

C.J.

. Fluoxetine administration in juvenile overfed rats improves hypothalamic mitochondrial respiration and REDOX status and induces mitochondrial biogenesis transcriptional expression.

173200

doi: 10.1016/j.ejphar.2020.173200

186

Scapagnini

, Sonya

, Nader

A.G.

, Calogero

, Zella

, Fabio

. Modulation of nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders.

doi: 10.1007/s12035-011-8181-5

187

Mendez-David

, Tritschler

, El Ali

, Damiens

M.-H.

, Pallardy

, David

D.J.

, Kerdine-Römer

, Gardier

A.M.

. Nrf2-signaling and BDNF: a new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression.

doi: 10.1016/j.neulet.2015.04.036

188

Hong

, Cao

, Wu

C.-F.

, Kadioglu

, Schüffler

, Kauhl

, Klauck

S.M.

, Opatz

, Thines

, Paul

N.W.

, Efferth

. The Chinese herbal formula Free and Easy Wanderer ameliorates oxidative stress through KEAP1-NRF2/HO-1 pathway.

11551

doi: 10.1038/s41598-017-10443-6

189

Perez-Leal

, Barrero

C.A.

, Merali

. Pharmacological stimulation of nuclear factor (erythroid-derived 2)-like 2 translation activates antioxidant responses.

doi: 10.1074/jbc.M116.770925

190

Robledinos-Antón

, Fernández-Ginés

, Manda

, Cuadrado

. Activators and inhibitors of NRF2: a review of their potential for clinical development.

doi: 10.1155/2019/9372182

191

Yammine

, Zarrouk

, Nury

, Vejux

, Latruffe

, Vervandier-Fasseur

, Samadi

, Mackrill

J.J.

, Greige-Gerges

, Auezova

, Lizard

. Prevention by dietary polyphenols (resveratrol, quercetin, apigenin) against 7-ketocholesterol-induced oxiapoptophagy in neuronal N2a cells: potential interest for the treatment of neurodegenerative and age-related diseases.

doi: 10.3390/cells9112346

192

Ghosh

, Patel

, Rahn

, McAllister

, Sadeghi

, Horwitz

, Berry

, Wang

K.X.

, Swerdlow

R.H.

. The thiazolidinedione pioglitazone alters mitochondrial function in human neuron-like cells.

doi: 10.1124/mol.106.033845

193

Komen

J.C.

, Thorburn

D.R.

. Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models.

doi: 10.1111/bph.12413

194

Mollo

, Nitti

, Zerillo

, Faicchia

, Micillo

, Accarino

, Secondo

, Petrozziello

, Calì

, Cicatiello

, Bonfiglio

, Sarnataro

, Genesio

, Izzo

, Pinton

, Matarese

, Paladino

, Conti

, Nitsch

. Pioglitazone improves mitochondrial organization and bioenergetics in down syndrome cells.

doi: 10.3389/fgene.2019.00606

195

Miglio

, Rattazzi

, Rosa

A.C.

, Fantozzi

. PPARgamma stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells.

doi: 10.1016/j.neulet.2009.03.014

196

Cerqueira

F.M.

, Laurindo

F.R.M.

, Kowaltowski

A.J.

. Mild mitochondrial uncoupling and calorie restriction increase fasting eNOS, akt and mitochondrial biogenesis.

e18433

doi: 10.1371/journal.pone.0018433

197

Schlagowski

A.I.

, Singh

, Charles

A.L.

, Gali Ramamoorthy

, Favret

, Piquard

, Geny

, Zoll

. Mitochondrial uncoupling reduces exercise capacity despite several skeletal muscle metabolic adaptations.

doi: 10.1152/japplphysiol.01177.2013

198

Farber

S.A.

, Slack

B.E.

, Blusztajn

J.K.

. Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease.

doi: 10.1096/fj.99-0853

199

Wasilewska-Sampaio

A.P.

, Silveira

M.S.

, Holub

, Goecking

, Gomes

F.C.A.

, Neto

V.M.

, Linden

, Ferreira

S.T.

, De Felice

F.G.

. Neuritogenesis and neuronal differentiation promoted by 2,4-dinitrophenol, a novel anti-amyloidogenic compound.

doi: 10.1096/fj.05-3812com

200

Freitas-Correa

, V Lourenco

, Acquarone

, da Costa

R.F.M.

, Galina

, Rehen

S.K.

, Ferreira

S.T.

. 2,4-Dinitrophenol induces neural differentiation of murine embryonic stem cells.

doi: 10.1016/j.scr.2013.09.016

201

Murphy

E.J.

, Schapiro

M.B.

, Rapoport

S.I.

, Shetty

H.U.

. Phospholipid composition and levels are altered in Down syndrome brain.

doi: 10.1016/s0006-8993(00)02205-8

202

Paula Lima

A.C.

, Arriagada

, Toro

, Cárdenas

A.M.

, Caviedes

, Ferreira

S.T.

, Caviedes

. Small-molecule aggregation inhibitors reduce excess amyloid in a trisomy 16 mouse cortical cell line.

doi: 10.4067/s0716-97602008000200001

203

Hasan-Olive

M.M.

, Lauritzen

K.H.

, Ali

, Rasmussen

L.J.

, Storm-Mathisen

, Bergersen

L.H.

. A ketogenic diet improves mitochondrial biogenesis and bioenergetics via the PGC1α-SIRT3-UCP2 Axis.

doi: 10.1007/s11064-018-2588-6

204

Rosebrough

R.W.

, Steele

N.C.

, Frobish

L.T.

. Effect of ketogenic diets in gestation on some characteristics of carbohydrate metabolism in fetal pig brain and liver.

205

Pliss

, Jatania

, Patel

M.S.

. Beneficial effect of feeding a ketogenic diet to mothers on brain development in their progeny with a murine model of pyruvate dehydrogenase complex deficiency.

doi: 10.1016/j.ymgmr.2016.03.012

206

Kaneko

. The ketogenic diet as a potential therapy in down syndrome.

doi: 10.29245/2578-2940/2018/2.1121

207

Pesini

, Iglesias

, Garrido

, Bayona-Bafaluy

M.P.

, Montoya

, Ruiz-Pesini

. OXPHOS, pyrimidine nucleotides, and Alzheimer's disease: a pharmacogenomics approach.

doi: 10.3233/JAD-140384

208

Lagerlöf

. O-GlcNAc cycling in the developing, adult and geriatric brain.

doi: 10.1007/s10863-018-9760-1

209

Pfenninger

K.H.

. Plasma membrane expansion: a neuron's Herculean task.

doi: 10.1038/nrn2593

210

López-Martín

J.M.

, Salviati

, Trevisson

, Montini

, DiMauro

, Quinzii

, Hirano

, Rodriguez-Hernandez

, Cordero

M.D.

, Sánchez-Alcázar

J.A.

, Santos-Ocaña

, Navas

. Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis.

doi: 10.1093/hmg/ddm058

211

Gross

T.J.

, Doran

, Cheema

A.K.

, Head

, Lott

I.T.

, Mapstone

. Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer's disease.

doi: 10.1002/dneu.22716

212

Gattermann

, Dadak

, Hofhaus

, Wulfert

, Berneburg

, Loeffler

M.L.

, Simmonds

H.A.

. Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration.

doi: 10.1081/NCN-200027545

213

Velazquez

, Ash

J.A.

, Powers

B.E.

, Kelley

C.M.

, Strawderman

, Luscher

Z.I.

, Ginsberg

S.D.

, Mufson

E.J.

, Strupp

B.J.

. Maternal choline supplementation improves spatial learning and adult hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome.

doi: 10.1016/j.nbd.2013.04.016

214

Wang

, Surzenko

, Friday

W.B.

, Zeisel

S.H.

. Maternal dietary intake of choline in mice regulates development of the cerebral cortex in the offspring.

doi: 10.1096/fj.15-282426

215

Wurtman

R.J.

. Synapse formation in the brain can be enhanced by co-administering three specific nutrients.

doi: 10.1016/j.ejphar.2017.09.038

216

Tayebati

S.K.

, Cecchi

, Martinelli

, Carboni

, Amenta

. Pharmacotherapy of down's syndrome: when and which?.

doi: 10.2174/1871527318666191114092924

Acknowledgments

We would like to thank Santiago Morales for his assistance with figures.